Bioorganic and Medicinal Chemistry Letters p. 4285 - 4288 (2003)
Update date:2022-08-04
Topics:
Perkins, James J.
Duong
Fernandez-Metzler, Carmen
Hartman, George D.
Kimmel, Donald B.
Leu, Chih-Tai
Lynch, Joseph J.
Prueksaritanont, Thomayant
Rodan, Gideon A.
Rodan, Sevgi B.
Duggan, Mark E.
Meissner, Robert S.
Antagonists of the integrin receptor αvβ3 are expected to have utility in the treatment of osteoporosis through inhibition of bone resorption. A series of potent, chain-shortened, pyrrolidinone-containing αvβ3 receptor antagonists is described. Two sets of diasteromeric pairs of high-affinity antagonists demonstrated marked differences in log P values, which translated into differing dog pharmacokinetic properties. One member of this set was demonstrated to be effective in reducing bone resorption in rats.
View MoreSHANDONG ZHANHUA YONGHAO PHARMACEUTICAL TECH.CO.,LTD
Contact:+86-576-88685096
Address:GENGJU VILLAGE NORTH ONE KILOMETER,ZHANHUA DISTRICT,BINZHOU CITY,SHANDONG PROVINCE,CHINA.
Jiangxi Dongxu Chemical Science & Technology Co.,Ltd
Contact:+86-791-86899381
Address:Nanchang, Jiangxi, China
Chengdu Gelipu Biotechnology Co., Ltd.
website:http://www.glp-china.com
Contact:86-28-82610909
Address:chegndu
Contact:86 21 3772 9386
Address:Rm.1803,Starry Bldg.1,1505 Meijiabang Road,Shanghai 201620 China
Jiangsu Allyrise Pharmaceutical Co., Ltd.(expird)
Contact:+86-523-86818997
Address:Taizhou,Jiangsu Province,CHINA
Doi:10.1021/ja01860a014
(1940)Doi:10.1016/S0040-4039(99)00577-8
(1999)Doi:10.1016/S0968-0896(02)00606-5
(2003)Doi:10.1039/j39690001346
(1969)Doi:10.1016/S0040-4020(99)00307-5
(1999)Doi:10.1016/S0031-9422(00)91376-1
(1974)